Journal article
Neurofilament light chain in psychiatric and neurodegenerative disorders: A ‘c‐reactive protein’ for the brain?
Dhamidhu Eratne, Samantha M Loi, Alexander Santillo, Qiao‐Xin Li, Carolyn Chadunow, Christiane Stehmann, Shorena Janelidze, Charles B Malpas, Nirbaanjot Walia, Shiji Varghese, Kunal Dhiman, Vicki Lewis, Mateo Senesi, Andrew H Evans, Wendy Kelso, Sarah Farrand, Amelia McGlade, Anita MY Goh, Christopher J Fowler, Lucy E Vivash Show all
Alzheimer's & Dementia | Wiley | Published : 2020
DOI: 10.1002/alz.041347
Abstract
AbstractBackgroundAccurate diagnosis of a neurodegenerative disorder, in particular distinguishing primary psychiatric from neurological disorders, can be challenging. There is a need for biomarkers to reduce the diagnostic odyssey and improve outcomes. Neurofilament light (NfL) has shown promise as a biomarker for diagnosis, staging and prognosis in a wide range of disorders. Our ‘Biomarkers in Younger Onset Neurocognitive Disorders’ (BeYOND) and ‘Markers in Neuropsychiatric Disorders’ (MiND) studies aim to build on our pilot study (Eratne et al, 2019, ANZJP), to explore the diagnostic and broader utility of plasma and cerebrospinal fluid (CSF) NfL, in a broad range of psychiatric and neuro..
View full abstract